Answers are grounded in this paper and cite their sources.
Computational comparative analysis reveals reduced proteasomal processing and fewer B-cell epitopes in SARS-CoV-2 versus SARS-CoV, suggesting distinct immune evasion strategies.
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-strand RNA virus belonging to the Coronaviridae family, responsible for coronavirus infectious disease 2019 (COVID-19) with the rapid transmission. This study aimed to characterize and compare SARS-CoV-2 and SARS-CoV major viral proteins and predict antigen proteasomal cleavage patterns, MHC class I processing and presentation, and B T-cell and anti-inflammatory epitopes. Methods: The amino acid sequences of spike surface (S) glycoprotein, membrane (M) glycoprotein, envelop (E) protein, and nucleocapsid (N) phosphoprotein was obtained from NCBI. The sequences were aligned by MEGA 7.0 and modeled by SWISS-MODEL. The proteasomal cleavage pattern, MHC class I processing, and T-cell epitopes were predicted via IEDB analysis and EPISOFT. The B-cell epitopes were predicted by BepiPred 2.0. Also, the prediction of anti-inflammatory epitopes was performed by AntiInflam. Results: Two major antigen proteins, S glycoprotein and M glycoprotein of SARS-CoV-2, respectively, showed 26.57% and 20.59% less efficiency in proteasomal cleavage and presentation to MHC class I, comparing SARS-CoV. There were fewer B-cell predicted epitopes in SARS-CoV-2, comparing SARS-CoV.
No takes yet. Share an insight, caveat, or question.
Maali et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: